title: The chances of a patient with melanoma developing in transit disease are doubled by undergoing sentinel lymph node biopsy (SLNB).
authors.forename: R
authors.initials: R
authors.lastname: Russell-Jones
authors.forename: A-M
authors.initials: AM
authors.lastname: Powell
authors.forename: K
authors.initials: K
authors.lastname: Acland
authors.forename: E
authors.initials: E
authors.lastname: Calonje
authors.forename: M
authors.initials: M
authors.lastname: O'Doherty
authors.forename: C
authors.initials: C
authors.lastname: Healy
mesh_terms: D006801:Humans; D008197:Lymph Node Excision; D008207:Lymphatic Metastasis; D008545:Melanoma / Q000453:epidemiology / Q000473:pathology* / Q000601:surgery; D009364:Neoplasm Recurrence, Local / Q000453:epidemiology* / Q000473:pathology*; D009367:Neoplasm Staging; D021701:Sentinel Lymph Node Biopsy; D012878:Skin Neoplasms / Q000453:epidemiology / Q000473:pathology* / Q000601:surgery